OVERALL The mission of The Jackson Laboratory Cancer Center (JAXCC) is to discover precise genomic solutions for cancer by making basic discoveries with human impact. Committed to our role as a basic research Cancer Center, we harness our transdisciplinary strengths in complex genetics and functional genomics to achieve this goal. Organized in a single research program, Genetic models for precision cancer medicine, the 53 full members combine the JAXCC's unique capabilities to model human cancers in mice with innovations in genomic and computational analytics of human cancers to attack this broad problem. From RNA biology to chromatin dynamics, from organismal to in silico models of cancer, from panels of genetically diverse strains to humanized mice, from single cell genomics to Patient Derived Xenografts, from genomic engineering technologies to genomic diagnostics?The JAXCC brings advanced technologies to bear on persistent cancer problems through collaborative partnerships with clinical investigators. Since 2013, we achieved unprecedented growth with 22 new members with expertise in immunology, computational biology, genomic technologies, epigenetics, microbiome, tumor microenvironment, and clinical genomics. The Shared Resources (Cancer Model Development Resource, Computational Sciences, Genetic Engineering Technologies, Genome and Single Cell Technologies, and Phenotyping Technologies) provide comprehensive support for this wide range of research. The collaborative environment, access to powerful technologies, and our use of Developmental Funds has yielded significant advances: in the past 5 years, we have more than doubled our funding from NCI and other cancer agencies and increased our overall intra-programmatic grant collaborative rate from 21% to 47%. Our translational impact includes development of therapeutics exploiting genomic instability; our role as a discovery engine for SWOG and our new community cancer genomic education initiative, the Maine Cancer Genomics Initiative. In the next five years, the JAXCC will harness the collective energy of our expanded Cancer Center. We will identify origins and the consequences of complex structural genomic alterations in cancer; we will craft genetically complex models of cancer to uncover the systems biology of the disease; we will explore the cellular dynamics of primary cancer cells in culture to uncover genetic causes of therapeutic insensitivity; and we will explore tumor-microenvironment interactions through in vivo and in vitro tissue reconstructions. Our goal in the next grant cycle is to bring several diagnostics and therapeutics to clinical development. In addition, we will establish a Cancer Education and Career Enhancement core that supports a continuum of learning for students, trainees, early career investigators and the Maine community oncology care providers. Our focus on complex genetics and functional genomics, the scale of our model creation and experimentation, and the integration of our diverse talents make the JAXCC a unique enterprise.

Public Health Relevance

OVERALL Genetic complexity and cellular heterogeneity are the greatest challenge to understanding and treating cancer. The Jackson Laboratory Cancer Center is focused on resolving this complexity through applying advanced computational and genomic approaches on novel organismal, cellular, and computational models of cancer, and by investigating the in vivo tumor-stromal-immune interactions. We translate our findings to the clinic through the provision of genetic and genomic technologies to key clinical collaborators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA034196-34
Application #
9854053
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
1997-08-01
Project End
2025-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
34
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Jackson Laboratory
Department
Type
DUNS #
042140483
City
Bar Harbor
State
ME
Country
United States
Zip Code
04609
Gong, Liang; Wong, Chee-Hong; Cheng, Wei-Chung et al. (2018) Picky comprehensively detects high-resolution structural variants in nanopore long reads. Nat Methods 15:455-460
Noorbakhsh, Javad; Kim, Hyunsoo; Namburi, Sandeep et al. (2018) Distribution-based measures of tumor heterogeneity are sensitive to mutation calling and lack strong clinical predictive power. Sci Rep 8:11445
Gatti, D M; Weber, S N; Goodwin, N C et al. (2018) Genetic background influences susceptibility to chemotherapy-induced hematotoxicity. Pharmacogenomics J 18:319-330
deCarvalho, Ana C; Kim, Hoon; Poisson, Laila M et al. (2018) Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat Genet 50:708-717
Mistri, Tapan Kumar; Arindrarto, Wibowo; Ng, Wei Ping et al. (2018) Dynamic changes in Sox2 spatio-temporal expression promote the second cell fate decision through Fgf4/Fgfr2 signaling in preimplantation mouse embryos. Biochem J 475:1075-1089
Leidy-Davis, Tiffany; Cheng, Kai; Goodwin, Leslie O et al. (2018) Viable Mice with Extensive Gene Humanization (25-kbp) Created Using Embryonic Stem Cell/Blastocyst and CRISPR/Zygote Injection Approaches. Sci Rep 8:15028
Raghupathy, Narayanan; Choi, Kwangbom; Vincent, Matthew J et al. (2018) Hierarchical analysis of RNA-seq reads improves the accuracy of allele-specific expression. Bioinformatics 34:2177-2184
Presa, Maximiliano; Racine, Jeremy J; Dwyer, Jennifer R et al. (2018) A Hypermorphic Nfkbid Allele Contributes to Impaired Thymic Deletion of Autoreactive Diabetogenic CD8+ T Cells in NOD Mice. J Immunol 201:1907-1917
Pullagura, Sri Ramulu N; Buaas, Bill; Gray, Nichelle et al. (2018) Functional Redundancy of DICER Cofactors TARBP2 and PRKRA During Murine Embryogenesis Does Not Involve miRNA Biogenesis. Genetics 208:1513-1522
Cho, Sung-Yup; Sung, Chang Ohk; Chae, Jeesoo et al. (2018) Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments. Blood 131:1931-1941

Showing the most recent 10 out of 1156 publications